Matches in Nanopublications for { ?s ?p "[TIL in bladder cancers could be labeled with a specific anti-VEGF mAb, indicating that TIL are likely to be able to secrete VEGF protein in situ at bioactive concentrations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 3 of
3
with 100 items per page.
- NP485772.RAObW6AmTqyPcrqb4inbOrvzZnMVGPmLj7UmjNXijXzW0130_assertion description "[TIL in bladder cancers could be labeled with a specific anti-VEGF mAb, indicating that TIL are likely to be able to secrete VEGF protein in situ at bioactive concentrations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP485772.RAObW6AmTqyPcrqb4inbOrvzZnMVGPmLj7UmjNXijXzW0130_provenance.
- assertion description "[TIL in bladder cancers could be labeled with a specific anti-VEGF mAb, indicating that TIL are likely to be able to secrete VEGF protein in situ at bioactive concentrations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1311925.RADXul4R2l1g86k0il-NBhAPsVaq8n_4lcHjv9JpnBzjg130_assertion description "[TIL in bladder cancers could be labeled with a specific anti-VEGF mAb, indicating that TIL are likely to be able to secrete VEGF protein in situ at bioactive concentrations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1311925.RADXul4R2l1g86k0il-NBhAPsVaq8n_4lcHjv9JpnBzjg130_provenance.